Extracorporeal shockwave therapy for Lifespan extension: Extracorporeal shockwave therapy prolongs mammalian life span via down regulation of angiotensin II type I receptor (AT1R), 22/June/2017, 11.32 pm

Extracorporeal Shock wave therapy for ageing-associated diseases: Extracorporeal Shock wave therapy increases NMN/NAD levels, decreases interaction of DBC1 with PARP1, increases PARP1 activity, promotes DNA repair, augments tolerance against radiation, cancer and aging via down regulation of its target gene, 22/June/2017, 11.30 pm
June 22, 2017
Molecular therapy for heart regeneration and repair: Astaxainthin, isolated from heaematococcus pluvialis, Pandalus, and Phaffia, increases Agrin expression, activates Yap and ERK-mediated signaling, replaces scar tissue with functional cardiomyocytes, and promotes cardiomyocyte regeneration and repair after myocardial infarction, via up regulation of its target gene, 22/June/2017, 11.33 pm
June 22, 2017
Show all

Significance of the study:

It has been shown earlier that antagonizing angiotensin II type I receptor (AT1R) expression may prolong mammalian life span. Further, it has been shown that disruption of AT1R (AGTR1) gene results in marked prolongation of mammalian lifespan. 


From research findings to therapeutic opportunity: 

This study suggests, for the first time, that Extracorporeal shockwave therapy, by increasing the expression of its target genes,  it may decrease the expression of AT1R.

Figure1. Mechanistic insights into how Extracorporeal shockwave therapy functions as a longevity-promoter. Extracorporeal shockwave therapy, by increasing the expression of its downstream target genes, down regulates A1TR expression and promotes mammalian longevity.

And, thereby, it may: (1) decrease blood pressure; (2) decrease blood sugar levels; (3) inhibit pulmonary fibrosis; (4) enhance bacterial immunity; (5) inhibit myocardial infarction; (6) increase telomerase expression, and decelerate ageing process; and (7) extend the lifespan of an individual.

Thus, physicians/gerontologists may consider encouraging their patients to undergo Extracorporeal shockwave therapy to lead a healthy and long-life.  Taken together, Extracorporeal shockwave therapy may be used to extend the lifespan of an individual (Figure 1)

Price 300[easy_payment currency=”USD”]


Details of the research findings: 

Idea Proposed/Formulated by:

Dr L Boominathan Ph.D.  

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Undisclosed mechanistic information: How  does Extracorporeal shockwave therapy suppress the expression of  angiotensin II type I receptor (AT1R)? 

Amount: $300#

For purchase and payment details, you may reach us at info@genomediscovery.org

#  Research cooperation


References

CitationBoominathan, L., Extracorporeal shockwave therapy for Lifespan extension: Extracorporeal shockwave therapy prolongs mammalian life span via down regulation of angiotensin II type I receptor (AT1R), 22/June/2017, 11.32 pm, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Web: http://genomediscovery.org or newbioideas.com/

Courtesy: When you cite drop us a line at info@genomediscovery.org

Comments are closed.